Zacks Research Research Analysts Lift Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Zacks Research boosted their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a research report issued on Tuesday, April 23rd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.23 per share for the quarter, up from their prior forecast of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at $0.45 EPS, Q1 2026 earnings at $1.14 EPS and FY2026 earnings at $3.59 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The firm’s revenue was up 545.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.50) earnings per share.

Several other brokerages also recently issued reports on APLS. Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $68.00 to $80.00 in a report on Monday, February 5th. Robert W. Baird restated an “outperform” rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. UBS Group lifted their price objective on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, March 4th. HC Wainwright restated a “buy” rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, April 15th. Finally, The Goldman Sachs Group lifted their price objective on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $77.93.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $49.93 on Wednesday. The company has a market cap of $6.02 billion, a PE ratio of -11.04 and a beta of 0.88. The company has a fifty day moving average price of $58.96 and a two-hundred day moving average price of $57.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $94.75.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently made changes to their positions in the business. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals in the 1st quarter worth approximately $29,000. First Horizon Advisors Inc. raised its holdings in shares of Apellis Pharmaceuticals by 69.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after purchasing an additional 265 shares in the last quarter. Covestor Ltd raised its holdings in shares of Apellis Pharmaceuticals by 564.2% during the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after purchasing an additional 677 shares in the last quarter. Stephens Consulting LLC bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $38,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 29.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after purchasing an additional 687 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 18,681 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total transaction of $1,068,179.58. Following the sale, the director now owns 173,998 shares in the company, valued at approximately $9,949,205.64. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the sale, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director A. Sinclair Dunlop sold 18,681 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total value of $1,068,179.58. Following the sale, the director now owns 173,998 shares in the company, valued at approximately $9,949,205.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 381,011 shares of company stock worth $23,463,657. 7.50% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).